Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Therapeutic-dose anticoagulation with heparin was evaluated in critically ill patients with Covid-19 to determine if it improved outcomes compared to usual-care pharmacologic thromboprophylaxis. The study, conducted as an open-label, adaptive, multiplatform randomized clinical trial, found no significant benefit in survival or organ support-free days. The trial was stopped early due to futility, with a high probability of inferiority for therapeutic-dose anticoagulation. Major bleeding events were slightly higher in the therapeutic-dose group (3.8% vs. 2.3%).

Therapeutic-dose anticoagulation with heparin was evaluated in critically ill patients with Covid-19 to determine if it improved outcomes compared to usual-care pharmacologic thromboprophylaxis. The study, conducted as an open-label, adaptive, multiplatform randomized clinical trial, found no significant benefit in survival or organ support-free days. The trial was stopped early due to futility, with a high probability of inferiority for therapeutic-dose anticoagulation. Major bleeding events were slightly higher in the therapeutic-dose group (3.8% vs. 2.3%).